Vallon Pharmaceuticals (VLON) Stock Price, News & Analysis

Company Overview

Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medications for central nervous system disorders with a focus on abuse-deterrent medications. Its lead investigational product candidate is ADAIR, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder (ADHD) and narcolepsy. The company is also developing ADMIR, an abuse deterrent formulation of methylphenidate for the treatment of ADHD. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.

Key Stats

• Today's Range: $0.60 to $0.64
• 50-Day Range: $0.27 to $2.87
• 52-Week Range: $0.21 to $12.92
• Volume: 124,322 shs
• Average Volume: 5.78 million shs
• Market Capitalization: $8.49 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

VLON Stock Analysis - Frequently Asked Questions

When did Vallon Pharmaceuticals' stock split?

Shares of Vallon Pharmaceuticals reverse split before market open on Monday, April 24th 2023. The 1-30 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did Vallon Pharmaceuticals IPO?

Vallon Pharmaceuticals (VLON) raised $15 million in an initial public offering on Wednesday, February 10th 2021. The company issued 1,700,000 shares at a price of $8.00-$10.00 per share. ThinkEquity (a division of Fordham Financial Management) served as the underwriter for the IPO.

What other stocks do shareholders of Vallon Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vallon Pharmaceuticals investors own include Meta Platforms (META), Alkaline Water (WTER), SoFi Technologies (SOFI), Exro Technologies (EXROF), AMC Entertainment (AMC), Alpha Lithium (APHLF) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Today: 1/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:VLON
• CUSIP: N/A
• CIK: 1824293
• Web: www.vallon-pharma.com
• Phone: 267-607-8255
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.78)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,020,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -230.48%
• Return on Assets: -124.89%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.29
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: $100,000.00
• Price / Sales: 84.94
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.18 per share
• Price / Book: 3.50

Miscellaneous

• Outstanding Shares: 13,482,000
• Free Float: 8,453,000
• Market Cap: $8.49 million
• Optionable: Not Optionable
• Beta: -1.14